Investing.com - Financial Markets Worldwide

Korea Pharma Co Ltd (032300)

KOSDAQ
Currency in KRW
14,130
-90(-0.63%)
Closed·

032300 Financial Summary

Key Ratios

P/E Ratio55.74
Price/Book2.34
Debt / Equity35.08%
Return on Equity4.25%
Dividend Yield0.35%
EBITDA8.88B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa71,509.7379,576.781,029.4283,240.4581,277.28
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa34,144.9535,897.535,41536,902.9735,150.32
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa4,603.575,014.076,187.125,840.386,086.47
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa3,159.116,368.34-1,119.0583.763,791.74
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa81,320.13129,401.35130,947.16121,303.37112,386.95
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa30,653.5925,498.469,535.3233,299.9519,320.75
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa46,502.2857,467.2159,815.4468,581.5371,441.42
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-4,674.011,003.551,395.41-1,693.312,638.5
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-873.847,192.468,279.254,819.458,046.29
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-4,710.95-12,908.45-51,875.3344,898.76-12,335.39
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa12,005.4145,362.54-4,563.12-16,660.62-15,296.47
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa6,421.4939,675.23-48,149.8433,034.15-19,515.85
* In Millions of KRW (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 273.96%
Dividend Yield
0.35%
Industry Median 0.94%
Annualised payout
50.00
Paid annually
5-Years Growth
-
Growth Streak
Unlock

Earnings

Latest Release
May 14, 2025
EPS / Forecast
47.19 / --
Revenue / Forecast
20.79B / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Korea Pharm's earnings for the latest quarter?

The Korea Pharm EPS (TTM) is 273.96. Korea Pharm reported sales of 20,786.00, net income of 514.67, and EPS of 47.19 for the latest quarter.

What was Korea Pharm's net income for the latest quarter?

Korea Pharm's net income for the latest quarter was 514.67.

How did Korea Pharm's performance compare year-over-year in the latest quarter?

The company's revenue moved from 21,944.20 in the previous quarter to 20,786.00 in the latest quarter, and net income moved from 56.16 to 514.67 compared to the previous quarter.

What is Korea Pharm's net profit margin on a TTM basis?

Korea Pharm's trailing twelve months (TTM) net profit margin is 4.67%.

How does Korea Pharm's debt to equity ratio compare to industry standards?

Korea Pharm's total debt-to-equity ratio is 35.08%.

What is Korea Pharm's return on investment on a TTM basis?

Korea Pharm's trailing twelve months (TTM) return on investment (ROI) is 4.25%.

Did Korea Pharm gain or lose cash last quarter?

In the latest quarter, Korea Pharm's net change in cash was 596.28 million.

What were Korea Pharm's total assets and liabilities in the latest quarter?

As of the latest quarter, Korea Pharm reported total assets of 117,092.16 million and total liabilities of 22,052.11 million.

How has Korea Pharm's total revenue grown this year?

Korea Pharm's total revenue was 21,944.20 in the previous quarter and 20,786.00 in the latest quarter.

What is Korea Pharm's gross margin on a TTM basis?

Korea Pharm's trailing twelve months (TTM) gross margin is 42.83%.

What was Korea Pharm's revenue per share for the latest quarter?

Korea Pharm's revenue per share for the latest quarter was 14,494.43.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.